drugset / Trial / NCT01921270
Dysport for the Treatment of OMD
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).
Timeline
- Start
- 2013-08
- Primary completion
- 2017-02-08
- Completion
- 2017-02-08
Publications
- Background Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999 Dec 10;53(9):2102-7. doi: 10.1212/wnl.53.9.2102.
- Background Rosales RL, Ng AR, Santos MM, Fernandez HH. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport(R)) injections for oromandibular, lingual, and truncal-axial dystonias. Int J Neurosci. 2011;121 Suppl 1:44-56. doi: 10.3109/00207454.2011.558260.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 7.5 iu | Other |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 10 iu | Other |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 25 iu | Other |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 50 iu | Other |